Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DSXP | ISIN: SE0009723125 | Ticker-Symbol: 65G
Frankfurt
06.06.25 | 08:04
0,083 Euro
-0,12 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXTCELL PHARMA AB Chart 1 Jahr
5-Tage-Chart
NEXTCELL PHARMA AB 5-Tage-Chart

Aktuelle News zur NEXTCELL PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoNEXTCELL PHARMA AB: NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors1
NEXTCELL PHARMA Aktie jetzt für 0€ handeln
28.05.NEXTCELL PHARMA AB: NextCell Pharma receives additional declarations of intent regarding exercise of TO21
28.05.NEXTCELL PHARMA AB: Angela Vollstedt joins NextCell Pharma's Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions1
26.05.NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm253NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent...
► Artikel lesen
23.05.NEXTCELL PHARMA AB: NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO21
20.05.NextCell, Fujifilm Irvine Scientific Enter Strategic Pact4
20.05.NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific636NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells...
► Artikel lesen
19.05.NEXTCELL PHARMA AB: Eric Strati Joins NextCell Pharma's Board of Advisors to Support Commercial Strategy for ProTrans1
16.05.NEXTCELL PHARMA AB: The exercise period for NextCell Pharma's warrants of series TO2 begins today-
15.05.NEXTCELL PHARMA AB: Eight-Year-Old Hugo - Living with Type 1 Diabetes and Participating in the ProTrans Study1
07.05.NEXTCELL PHARMA AB: Study published in Nature Medicine shows promising results in Alzheimer's disease - supports the development of ProTrans at NextCell2
25.04.NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/202578NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report....
► Artikel lesen
24.04.NEXTCELL PHARMA AB: NextCell presents detailed analysis of the administrative report from ProTrans-Young1
23.04.NEXTCELL PHARMA AB: NextCell Presents Quarterly Report4
15.04.NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward96NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the...
► Artikel lesen
07.04.NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young1
28.03.NEXTCELL PHARMA AB: NextCell's CSO Appointed to the Board of ATMP Sweden5
19.03.NEXTCELL PHARMA AB: Recognition for NextCell's CSO from the International Society of Cell and Gene Therapy1
13.03.NextCell Pharma AB: Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv363NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12-21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month...
► Artikel lesen
19.02.NEXTCELL PHARMA AB: All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study1
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1